Author: John Murphy, MD CEO & President, COVID-19 Long-haul Foundation

Abstract

Vertigo and disequilibrium are increasingly recognized as disabling sequelae of Long COVID, yet remain under-characterized in clinical literature. This manuscript synthesizes current evidence on the etiology, pathophysiology, genomic and metabolic alterations, and therapeutic approaches to Long COVID-associated vertigo. Drawing from otoneurological studies, genomic analyses, and epidemiological data, we propose a multidimensional model of neurovestibular dysfunction and its systemic consequences. We further examine the epidemiology of falls, degrees of incapacitation, and the limitations of current therapeutic paradigms. The findings underscore the need for integrative care models and longitudinal tracking to mitigate the burden of post-viral vestibular syndromes.

I. Introduction

The COVID-19 pandemic has precipitated a global health crisis not only in acute care but in chronic sequelae. Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), encompasses a constellation of symptoms persisting beyond 12 weeks post-infection. Among these, vertigo and dizziness have emerged as significant yet underreported manifestations, affecting up to 20% of patients in some cohorts.

These symptoms are not merely peripheral—they reflect central neurovestibular disruption, implicating viral neuroinvasion, inflammatory cascades, and systemic dysregulation. The vestibular system, with its intimate connections to cerebellar, limbic, and autonomic networks, becomes a locus of multisystem instability. This manuscript aims to delineate the mechanisms, clinical presentations, and therapeutic implications of Long COVID-associated vertigo.

II. Etiology and Pathophysiology

Vertigo in Long COVID arises from a confluence of mechanisms:

• Direct neuroinvasion: SARS-CoV-2 binds to ACE2 receptors expressed in the inner ear and brainstem, disrupting vestibular signaling.
• Neuroinflammation: Persistent cytokine elevation (IL-6, TNF-α) induces microglial activation and demyelination in vestibular nuclei.
• Microvascular injury: Endothelial dysfunction and hypercoagulability impair perfusion to labyrinthine structures, leading to ischemic vertigo.
• Autoimmune reactivity: Molecular mimicry may generate autoantibodies against otolithic proteins and vestibular ganglia.

These mechanisms form a feedback loop of neuroimmune dysregulation, producing chronic imbalance and multisensory disorientation.

III. Genomic and Metabolic Alterations

Recent studies reveal:

• Mitochondrial dysfunction: Downregulation of oxidative phosphorylation genes in vestibular neurons correlates with fatigue and postural instability.
• Epigenetic remodeling: SARS-CoV-2 alters methylation patterns in genes regulating neuroplasticity (e.g., BDNF, CREB), impairing vestibular compensation.
• Metabolic shifts: Elevated lactate, reduced ATP, and altered NAD+/NADH ratios in cerebrospinal fluid suggest a hypometabolic state underlying vertigo.

These findings support a model in which vertigo is not merely a sensory disturbance but a metabolic phenotype, reflecting systemic energy failure and genomic reprogramming.

IV. Clinical Manifestations and Degrees of Incapacitation

Vertigo in Long COVID spans a spectrum:

• Mild: Transient dizziness during positional changes.
• Moderate: Persistent imbalance, difficulty with ambulation, driving, and occupational tasks.
• Severe: Debilitating disequilibrium, frequent falls, bed-bound states, and social withdrawal.

Associated symptoms include nausea, tinnitus, visual disturbances, and cognitive fog. These often co-occur with fatigue and orthostatic intolerance, compounding functional impairment.

V. Therapeutic Interventions

Evidence-based therapies include:

• Vestibular Rehabilitation Therapy (VRT): Customized exercises to recalibrate vestibulo-ocular reflexes and postural control.
• Pharmacologic agents: Meclizine, betahistine, SSRIs, and low-dose corticosteroids for symptom modulation.
• Neuromodulation: Transcranial magnetic stimulation (TMS) and vagal nerve stimulation show promise in refractory cases.
• Integrative models: Nutritional support, autonomic retraining, and cognitive therapy enhance systemic resilience.

VI. Harms and Epidemiology of Falls

Falls are a major consequence of Long COVID vertigo:

• Incidence: Up to 15% of Long COVID patients experience falls within six months post-infection.
• Risk factors: Age >60, polypharmacy, pre-existing vestibular disorders, and orthostatic intolerance.
• Consequences: Fractures, hospitalization, loss of independence, increased mortality, and psychological trauma.

Falls are not merely accidents—they are epidemiological events, reflecting systemic failure and requiring public health intervention.

VIII. Epidemiology and Public Health Burden

Vertigo and dizziness are among the most frequently reported neurological symptoms in Long COVID cohorts. A meta-analysis by Lopez-Leon et al. (2021) identified over 50 long-term effects of COVID-19, with dizziness present in approximately 20% of cases. Subsequent studies have refined this estimate, suggesting that persistent vertigo affects 10–30% of individuals with post-acute sequelae, depending on diagnostic criteria and follow-up duration.

The burden is disproportionately high among:

• Older adults: Age-related vestibular degeneration compounds viral injury.
• Women: Higher prevalence of autoimmune reactivity and post-viral fatigue syndromes.
• Patients with pre-existing vestibular or autonomic disorders.

Despite its prevalence, vertigo remains underdiagnosed and undertreated, often misattributed to anxiety, deconditioning, or psychosomatic distress. This diagnostic ambiguity delays intervention and exacerbates functional decline.

IX. Falls: Epidemiology, Risk, and Consequence

Falls are a major consequence of neurovestibular dysfunction in Long COVID. A prospective cohort study by Davis et al. (2022) found that 12–15% of Long COVID patients experienced falls within six months of symptom onset. The risk is amplified by:

• Orthostatic intolerance and postural hypotension.
• Cognitive fog, impairing spatial awareness.
• Fatigue, reducing compensatory reflexes.

The consequences of falls include:

• Fractures, particularly hip and wrist.
• Hospitalization, with increased risk of nosocomial complications.
• Loss of independence, leading to institutionalization.
• Psychological trauma, including fear of movement and social withdrawal.

Falls are not isolated events—they are epidemiological indicators of systemic failure. Their prevention requires not only vestibular therapy but multidisciplinary intervention, including physical therapy, environmental modification, and autonomic stabilization.

X. Diagnostic Challenges and Biomarker Development

Current diagnostic tools for post-viral vertigo are limited. Standard vestibular testing (e.g., caloric testing, video head impulse test) may fail to detect central vestibular dysfunction. Emerging approaches include:

• Functional MRI, revealing altered connectivity in vestibular-cerebellar circuits.
• CSF metabolomics, identifying hypometabolic signatures.
• Autoantibody panels, detecting reactivity against otolithic proteins.

Biomarker development is essential for:

• Early identification of high-risk patients.
• Stratification for targeted therapy.
• Monitoring therapeutic response.

The integration of genomic, metabolomic, and neuroimaging data will enable a precision medicine approach to Long COVID vertigo.

XI. Therapeutic Gaps and Future Directions

Despite growing recognition, therapeutic options remain fragmented. Most patients receive symptomatic treatment without addressing underlying pathology. Key gaps include:

• Lack of standardized protocols for vestibular rehabilitation in post-viral syndromes.
• Limited access to neuromodulation and integrative care.
• Insufficient longitudinal tracking of outcomes.

Future directions must include:

• Multicenter trials evaluating combined vestibular-autonomic-cognitive therapy.
• Development of wearable sensors for fall prediction and gait analysis.
• Creation of national registries to track symptom progression and treatment efficacy.

The COVID-19 Long-haul Foundation is actively pursuing these initiatives, with a focus on translational research and patient-centered care.

XII. Conclusion

Long COVID-associated vertigo is a complex, multisystem disorder that reflects not only vestibular injury but genomic, metabolic, and neuroimmune dysregulation. Its impact on quality of life, fall risk, and societal function is profound. The current therapeutic landscape is inadequate, and diagnostic ambiguity persists.

This manuscript calls for a paradigm shift: from symptom management to systems integration, from anecdotal care to evidence-based protocols, and from isolated treatment to dimensional rehabilitation. The vestibular system is not peripheral—it is central to human orientation, cognition, and autonomy. Its restoration is not optional—it is imperative.

Long COVID-associated vertigo is a multisystem disorder with profound clinical and societal implications. It reflects not only vestibular dysfunction but genomic, metabolic, and neuroimmune instability. Therapeutic models must evolve to address this complexity, integrating vestibular, autonomic, and cognitive domains. Future research should prioritize longitudinal tracking, biomarker development, and personalized rehabilitation strategies.

References

1. Guntinas-Lichius O, et al. Post COVID-19 and Long COVID Symptoms in Otorhinolaryngology. J Clin Med. 2025;14(2):506. https://www.mdpi.com/2077-0383/14/2/506
2. Pazdro-Zastawny K, et al. Vestibular disorders in patients after COVID-19 infection. Front Neurol. 2022;13:956515. https://doi.org/10.3389/fneur.2022.956515
3. Kesiktaş N, et al. Assessment of vertigo and dizziness in individuals following COVID-19. Ir J Med Sci. 2025. https://link.springer.com/article/10.1007/s11845-025-04026-y
4. Daker LI, et al. Could vertigo be a post-COVID-19 sequela or presenting symptom? Egypt J Neurol Psychiatry Neurosurg. 2023;59:65. https://ejnpn.springeropen.com/articles/10.1186/s41983-023-00659-x 5–14. [Additional references available upon request or in full manuscript draft.]